BRCA2 and breast neoplasm: These features, together with the presence of inactivating mutations in the BRCA1 and BRCA2 genes, are captured by genomic diagnostic tests currently used in clinical practice to identify HRd ovarian and breast tumours that are more likely to benefit from PARP1 inhibitors [5].